Clinical

GLP-1 Drug Interactions: The Three That Change Management

Most interactions in this class run through one mechanism — slowed gastric emptying reducing oral absorption — and for most medications that is theoretical. Three are not

One mechanism, three consequences

Tirzepatide and semaglutide slow gastric emptying. Anything swallowed therefore leaves the stomach more slowly and is absorbed more slowly, and sometimes less completely.

For the large majority of oral medications this makes no clinical difference. It matters in three situations, and knowing which they are is more useful than a list of everything that has ever been co-prescribed.

The third is the one most often missed because it is not an absorption interaction at all — which is why checking a general interaction database can under-flag it.

1. Oral contraceptives

The most actionable interaction in this class, and the one with a specific published window. The label advises switching to a non-oral method or adding a barrier method for four weeks after initiation and for four weeks after each dose increase.

The precaution attaches to change, so it recurs at every dose step rather than applying once. Given GLP-1s are not recommended in pregnancy and the tirzepatide label notes potential fetal harm, this is worth raising before the first dose rather than after. Covered in full on our contraception page.

2. Narrow-therapeutic-index drugs

Warfarin is the standard example. It requires a blood level within a narrow band, and changes in absorption can move that band in either direction. The consequence of drifting low is clotting; drifting high is bleeding.

The management is not usually avoidance but monitoring — more frequent checks around initiation and each dose increase, which are the points where gastric emptying changes most. Anyone on warfarin should have their anticoagulation clinic told they are starting a GLP-1.

The same logic applies to other narrow-index drugs. The question to ask a pharmacist is not "does this interact" but "is this a drug where a small absorption change matters".

3. Insulin and sulfonylureas

This one is different in kind. It is not about absorption at all — it is that two glucose-lowering agents together lower glucose more than either alone.

Adding a GLP-1 to insulin or a sulfonylurea such as glimepiride or glipizide raises hypoglycaemia risk, and the dose of the existing agent may need reducing before the GLP-1 is started rather than after a hypoglycaemic episode.

There is a related point that catches people months into treatment: doses of many medications are calibrated to a body weight that is now falling. Antihypertensives in particular frequently need review as weight comes down, and the symptom that prompts it is often dizziness or fatigue attributed to the GLP-1.

What is not on this list, and why

That last row matters for anyone considering a compounded product alongside a branded one, which is a combination people arrive at when supply is interrupted.

What to bring to a pharmacist

1. A complete list including anything bought without a prescription.
2. Which of them are time-critical or narrow-index.
3. Your dose-increase schedule, since that is when absorption shifts.
4. Whether anyone is reviewing your other doses as your weight falls.

A pharmacist can answer this in minutes and has your full record. A general interaction checker will not flag the third category at all, because additive glucose lowering is not what those tools look for.

Questions readers actually ask